Azeliragon

Azeliragon

CAT N°: 24678
Price:

From 92.00 78.20

Azeliragon is an orally bioavailable inhibitor of the receptor for advanced glycation endproducts (RAGE; Kd = 12.7 nM for human recombinant sRAGE), which transports amyloid-? (A?) from plasma into the CNS.{39734} It is selective for sRAGE over greater than 100 receptors and transporters in a screening assay. Azeliragon (0.3, 1, and 3 mg/kg per day) prevents brain deposition of A? (1-40) (A?40) and A?42 in the APP/SWE/LON transgenic mouse model of Alzheimer’s disease and increases plasma A? levels when administered for three months starting at 12 months of age. In the same treatment paradigm, it dose-dependently reduces memory impairments in the Morris water maze compared with untreated control mice, decreasing the latency and distance traveled to the platform. Azeliragon (10 mg/kg) also increases cerebral blood flow in the hippocampus and frontal cortex in tgAPP/SWE/LON mice greater than six months old.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-4-yl]phenoxy]-N,N-diethyl-1-propanamine
  • Correlated keywords
    • 40 42
  • Product Overview:
    Azeliragon is an orally bioavailable inhibitor of the receptor for advanced glycation endproducts (RAGE; Kd = 12.7 nM for human recombinant sRAGE), which transports amyloid-? (A?) from plasma into the CNS.{39734} It is selective for sRAGE over greater than 100 receptors and transporters in a screening assay. Azeliragon (0.3, 1, and 3 mg/kg per day) prevents brain deposition of A? (1-40) (A?40) and A?42 in the APP/SWE/LON transgenic mouse model of Alzheimer’s disease and increases plasma A? levels when administered for three months starting at 12 months of age. In the same treatment paradigm, it dose-dependently reduces memory impairments in the Morris water maze compared with untreated control mice, decreasing the latency and distance traveled to the platform. Azeliragon (10 mg/kg) also increases cerebral blood flow in the hippocampus and frontal cortex in tgAPP/SWE/LON mice greater than six months old.

We also advise you